Antiangiogenic chemotherapeutic agents: Characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models

Clinical Cancer Research

Volumn 4, Issue 5, 1998, Pages 1331-1336

  Schirner, Michael ^a   Hoffmann, Jens ^b   Menrad, Andreas ^a   Schneider, Martin R ^a  

^a BAYER PHARMA AG   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; VINCRISTINE;

ANGIOGENESIS; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL GROWTH; DRUG EFFECT; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY CARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL DIVISION; FEMALE; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; SUBRENAL CAPSULE ASSAY;

EID: 0031948807     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst., 82: 4-6, 1990.
2. Gasparini, G., and Harris, A. L. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J. Clin. Oncol., 13: 765-782, 1995.
3. Ferrara, N. Vascular endothelial growth factor - the trigger for neovascularization in the eye. Lab. Invest., 72: 615-618, 1995.
4. Lazo, J. S. Endothelial injury caused by antineoplastic agents. Biochem. Pharmacol., 35: 1919-1923, 1986.
5. Denekamp, J. Endothelial cell proliferation as a novel approach to targeting tumor therapy. Br. J. Cancer, 45: 136-139, 1982.
6. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (Lond.), 362: 841-844, 1992.
7. Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., and Folkman, J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature (Lond.), 348: 555-557, 1990.
8. Teicher, B. A., Sotomayor, E. A., and Huang, Z. D. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res., 52: 6702-6704, 1992.
9. Braddock, P. S., Hu, D. E., Fan, T. P., Stratford, I. J., Harris, A. L., and Bicknell, R. Vascular targeting and the inhibition of angiogenesis. Ann. Oncol., 5 (Suppl. 4): 45-50, 1994.
10. Kerbel, R. S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays, 13: 31-36, 1991.
11. Tannock, I. Population kinetics of carcinoma cells, capillary endothelial cells and fibroblasts in a transplanted mouse mammary tumor. Cancer Res., 30: 2470-2476, 1970.
12. Hobson, B., and Denekamp, J. Endothelial cell proliferation in tumors and normal tissue: continuous labelling studies. Br. J. Cancer, 49: 405-413, 1984.
13. Hill, S. A., Lonergan, S. J., Denekamp, J., and Chaplin, D. J. Vinca alkaloids: anti-vascular effects in a murine tumor. Eur. J. Cancer, 29: 1320-1324, 1993.
14. Steiner, R. Angiostatic activity of anticancer agents in the chick embryo chorioallantoic membrane (CHE-CAM) assay. In: R. Steiner, P. B. Weisz, and R. Langer (eds.), Angiogenesis, pp. 449-454. Basel: Birkhäuser Verlag, 1992.
15. Maragoudarkis, M. E., Peristeris, P., Missirlis, E., Aletras, A., Andriopolou, P., and Haralabopoulous, G. Inhibition of angiogenesis by anthracyclines and titanocene dichloride. Ann. NY Acad. Sci., 732: 280-293, 1994.
16. Fox, S. B., Gatter, K. C., Bicknell, R., Going, J. J., Stanton, P., Cooke, T. G., and Harris, A. L. Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res., 53: 4161-4163, 1993.
17. Hoffmann, J., Schirner, M., Menrad, A., Schneider, M. R. A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells. Cancer Res., 57: 3847-3851, 1997.
18. Plunkett, M. L., and Hailey, J. A. An in vivo quantitative angiogenesis model using tumor cells entrapped in alginate. Lab. Invest., 62: 510-517, 1990.
19. Robertson, N. E., Discafani, C. M., Downs, E. C., Hailey, J. A., Sarre, O., Runkle, R. L. J., Popper, T. L., and Plunkett, M. L. A quantitative in vivo mouse model used to assay inhibitors of tumor-induced angiogenesis. Cancer Res., 51: 1339-1344, 1991.
20. Vorlop, K. D., and Klein, J. New developments in the field of cell immobilization-formation of biocatalysts by ionotropic gelation. In: R. M. Lafferty (ed.), Enzyme Technology, pp. 219-235. Berlin: Springer Verlag, 1983.
21. Weidner, N., Carroll, P. R., Flax, J., Blumenfeld, W., and Folkman, J. Tumor angiogenesis correlates with metastasis in invasive prostate cancer. Am. J. Pathol., 143: 401-409, 1993.
22. Giard, D. J., Aaronson, S. A., Todaro, G. J., Arnstein, P., Kersey, J. H., Dosik, H., and Parks, W. P. In vitro cultivation of human tumors: establishment of cell lines derived from series of solid tumors. J. Natl. Cancer Inst., 51: 1417-1423, 1973.
23. Fogh, J., Fogh, J. M., and Orfeo, T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst., 59: 221-226, 1977.
24. Korhonen, M., Sariola, H., Gould, V. E., Kangas, L., and Virtanen, I. Integrins and laminins in human renal carcinoma cells and tumors grown in nude mice. Cancer Res., 54: 4532-4538, 1994.
25. Orr, F. W., Adamson, I. Y. R., and Young, L. Promotion of pulmonary metastasis in mice by bleomycin-induced endothelial injury. Cancer Res., 46: 891-897, 1986.
26. Harrison, J. H., and Lazo, J. S. High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis. J. Pharmacol. Exp. Ther., 243: 1185-1194, 1988.
27. Hill, S. A., Sampson, L. E., and Chaplin, D. J. Anti-vascular approaches to solid tumor therapy: evaluation of vinblastine and flavone acid. Int. J. Cancer, 63: 119-123, 1995.
28. Baguley, B. C., Holdaway, K. M., Thomsen, L. L., Zhuang, L., and Zwi, L. J. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur. J. Cancer, 27: 482-487, 1991.
29. Carmal, R. J., and Brown, J. M. The effect of cyclophosphamide and other drugs on the incidence of pulmonary metastases in mice. Cancer Res., 37: 145-151, 1977.
30. Abe, J., Zhou, W., Takuwa, N., Taguchi, J., Kurokawa, K., Kumada, M., and Takuwa, Y. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res., 54: 3407-3412, 1994.
31. 1 phase of the cell cycle. Cancer Res., 54: 2073-2076, 1994.
32. Kato, T., Sato, K., Kakinuma, H., and Matsuda, Y. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamyl-fumagillol-TNP.470) and cytotoxic agents in mice. Cancer Res., 54: 5143-5147, 1994.